Understanding AMH Levels in Healthy Girls
Anti-mullerian Hormone Levels in Healthy Females
This study is trying to find out the normal levels of a hormone called AMH in girls aged 0-18 to help understand their reproductive health and fertility options, especially for young cancer patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | N/A to 18 Years |
| Sex | Female |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT04537390 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the normal blood levels of anti-mullerian hormone (AMH) in females aged 0-18 years and how these levels relate to their reproductive development. By collecting blood samples from pre- and post-pubertal females undergoing routine outpatient surgical procedures, researchers hope to establish a baseline for AMH levels in this population. This understanding could help assess the risk of infertility in young cancer patients and provide options for preserving fertility. The study focuses on a specific age group and aims to fill the knowledge gap regarding AMH levels in children and adolescents.
Who should consider this trial
Good fit: Ideal candidates are pre- and post-pubertal females aged 0-18 years who are undergoing routine outpatient surgical procedures.
Not a fit: Patients with a history of conditions associated with premature ovarian failure or those who have undergone cancer treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve fertility preservation strategies for young females at risk of infertility due to cancer treatments.
How similar studies have performed: While studies on AMH levels in adults have shown success, this specific focus on children and adolescents is relatively novel and less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pre- and post-pubertal females 2. Ages 0-18 years old 3. Tanner Stage I- V 4. Undergoing routine outpatient surgical procedure 1. Hernia repair (inguinal, umbilical, epigastric) 2. Excision of benign mass 3. laparoscopic cholecystectomy Exclusion Criteria: 1. Previous diagnosis of an illness associated with premature ovarian failure (Turner's syndrome, Fragile X permutation carrier) or endocrine disorder associated with irregular menstrual cycles (Cushing's disease, poorly-controlled Thyroid disease, hyperprolactinemia, polycystic ovary syndrome, and congenital adrenal hyperplasia) or insulin-dependent diabetes mellitus or autoimmune disorders 2. Previous diagnosis of any malignancy or any history of systemic/local chemotherapy, radiation therapy, or stem-cell transplant. 3. Previous surgical excision of one ovary or both ovaries 4. Pregnant females 5. All inpatient surgical patients 6. Undergoing non-routine outpatient surgical procedures 1. Central venous catheter placement 2. Supprelin insertion/removal 3. Breast mass excision 4. Gastrostomy tube insertion
Where this trial is running
Chicago, Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Erin Rowell, MD — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Jacquelyn Searcy
- Email: FertilityPreservationMB@luriechildrens.org
- Phone: 3122274758
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.